StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $2.65 | $2.58 | -2.64% | 0.1M |
| 05-12 | $2.58 | $2.58 | +0.00% | 0.1M |
| 05-13 | $2.59 | $2.48 | -4.25% | 0.1M |
| 05-14 | $2.44 | $2.32 | -4.92% | 0.4M |
| 05-15 | $2.29 | $2.07 | -9.61% | 0.2M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $8.00M | $33.59M | $22.30M | $14.47M |
Operating Income | $-13.85M | $-47.39M | $-35.18M | $-23.81M |
Net Income | $-14.28M | $-47.12M | $-34.63M | $-11.86M |
EPS (Diluted) | $-0.31 | $-1.05 | $-0.78 | $-0.52 |
Total Assets | $62.36M | $74.85M | $84.41M | $75.59M |
Total Liabilities | $41.97M | $41.65M | $40.08M | $21.04M |
Cash & Equivalents | $13.81M | $20.03M | $18.95M | $18.33M |
Free Cash Flow OCF − CapEx | $-15.45M | $-31.91M | $-28.57M | $-19.45M |
Shares Outstanding | 45.43M | 44.68M | 44.53M | 44.32M |
No sell-side coverage available for RPID.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for RPID.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.